Table 3 from The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. | Semantic Scholar
Fibroscan®
Biomarkers Good at Predicting NAFLD or Excluding Advanced Fibrosis With HIV (FibroScan, CAP Score)
FibroScan® Fat Results - Tawazun Health
A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis | PLOS ONE
My FibroScan Experience and Test Results
Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates - ScienceDirect
FibroScan® by echosens machine, ultrasound technology, cost - ECHOSENS
Frontiers | Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement
FibroScan - Because liver health matters
FibroScan® with CAP™ for fatty liver disease assessment - ECHOSENS
Alcohol Liver Damage | FibroScan
RACGP - FibroScan and transient elastography
FibroScan Reporting Guidelines
PDF] Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. | Semantic Scholar
Cureus | Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease | Article
Fibroscan
The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases | Scientific Reports